No Data
No Data
Lianhuan Pharma Obtains China Registration Approval for Antihistamine
Jiangsu Lianhuan Pharmaceutical (SHA:600513) obtained a drug registration certificate from China's National Medical Products Administration for its ebastine oral solution, according to a filing with t
Express News | Lianhuan Pharmaceutical: Obtained the drug registration certificate for evastine oral solution
Express News | Lianhuan Pharmaceutical: Midana's new tablet received a notice of approval for clinical trials of the drug
Lianhuan Pharmaceutical (600513.SH): Request the shareholders' meeting to authorize matters relating to issuing shares to specific targets through simple procedures
Gelonghui, March 18 | Lianhuan Pharmaceutical (600513.SH) announced that the board of directors of the company requested the 2023 annual shareholders' meeting to authorize the board of directors to handle matters relating to issuing shares with total financing not exceeding RMB 300 million and not exceeding 20% of net assets at the end of the most recent year to specific targets. The authorization period is from the date of consideration and approval of the 2023 Annual General Meeting of Shareholders to the date of the 2024 Annual General Meeting of Shareholders.
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its Problems
Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s (SHSE:600513) recent weak earnings report didn't cause a big stock movement. We think that investors are worried about some weaknesses underlying the earni
Lianhuan Pharmaceutical (600513.SH): Net profit in 2023 fell 4.5% year-on-year, and plans to pay 10 to 1.5 yuan
On March 5, Ge Longhui Pharmaceutical (600513.SH) released its 2023 annual report. Operating revenue was 2.174 billion yuan, up 11.20% year on year, net profit of 135 million yuan, down 4.5% year on year, after deducting non-net profit of 116 million yuan, down 13.27% year on year, and basic earnings per share of 0.47 yuan. It is proposed to distribute a cash dividend of 1.5 yuan for every 10 shares to all shareholders.
No Data